Field & Main Bank’s Novo Nordisk NVO Stock Holding History

Field & Main Bank’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-54	Closed	-$3K	–	314
2022 Q2	$3K	Buy	+54	New	+$3K	﹤0.01%	307

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Field & Main Bank's NVO Position: Q3 2022 in Review

Field & Main Bank sold out of Novo Nordisk (NVO) in Q3 2022, closing a stake of 54 shares — an estimated $3K sold.

Field & Main Bank first reported a position in NVO in Q2 2022 and held it in 1 quarter. The position peaked at $3K in Q2 2022. 907 funds tracked by Wall St. Rank hold NVO as of Q3 2022.

Field & Main Bank reported no remaining Novo Nordisk position as of Q3 2022 after selling out during the quarter.
Field & Main Bank sold 54 Novo Nordisk shares in Q3 2022, an estimated $3K.
Field & Main Bank first reported a position in Novo Nordisk in Q2 2022 and held it in 1 quarter.
Field & Main Bank's Novo Nordisk position peaked at $3K in Q2 2022.
907 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2022.

Based on Field & Main Bank's 13F filing for Q3 2022, filed 25 Oct 2022.